Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib

Ryuichi Mizuno, Shuji Mikami, Kimiharu Takamatsu, Toshiaki Shinojima, Eiji Kikuchi, Mototsugu Oya

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: To elucidate the clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with axitinib. Methods: A total of 58 patients were retrospectively analyzed. All patients received axitinib treatment for mRCC at Keio University hospital in Japan. Baseline clinical factors and on treatment adverse events were assessed to predict survival. Results: The median progression free survival (PFS) for axitinib treatment was 10.9 months (95% CI 5.8-13.5), and the median overall survival (OS) from the start of axitinib treatment was 39.8 months (95% CI 25.9-NR), respectively. The PFS (P < 0.0001) and OS (P = 0.0022) were significantly correlated with the International mRCC Database Consortium (IMDC) classification, respectively. The PFS and OS were significantly longer in patients who received longer prior treatment (P = 0.0424 and 0.0067, respectively). On-treatment hypertension, hand foot syndrome and hypothyroidism were associated with longer PFS (P = 0.0002, 0.0055 and 0.0290, respectively). Ontreatment hypertension, diarrhea, and hand foot syndrome were associated with longer OS (P = 0.0004, 0.0036 and 0.0115, respectively). Conclusions: Baseline and on treatment factors are identified as prognostic markers in mRCC patients treated with axitinib. Our findings might be helpful for clinicians to select the best treatment to individual patients.

Original languageEnglish
Pages (from-to)1170-1174
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume47
Issue number12
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Renal Cell Carcinoma
Disease-Free Survival
Survival
Hand-Foot Syndrome
Therapeutics
Hypertension
axitinib
Hypothyroidism
Diarrhea
Japan
Databases

Keywords

  • Axitinib
  • Metastasis
  • Molecular targeted therapy
  • Outcome
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib. / Mizuno, Ryuichi; Mikami, Shuji; Takamatsu, Kimiharu; Shinojima, Toshiaki; Kikuchi, Eiji; Oya, Mototsugu.

In: Japanese Journal of Clinical Oncology, Vol. 47, No. 12, 01.12.2017, p. 1170-1174.

Research output: Contribution to journalArticle

@article{b454dd9f2ebd4cb9a6b09bed0b61c6a5,
title = "Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib",
abstract = "Background: To elucidate the clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with axitinib. Methods: A total of 58 patients were retrospectively analyzed. All patients received axitinib treatment for mRCC at Keio University hospital in Japan. Baseline clinical factors and on treatment adverse events were assessed to predict survival. Results: The median progression free survival (PFS) for axitinib treatment was 10.9 months (95{\%} CI 5.8-13.5), and the median overall survival (OS) from the start of axitinib treatment was 39.8 months (95{\%} CI 25.9-NR), respectively. The PFS (P < 0.0001) and OS (P = 0.0022) were significantly correlated with the International mRCC Database Consortium (IMDC) classification, respectively. The PFS and OS were significantly longer in patients who received longer prior treatment (P = 0.0424 and 0.0067, respectively). On-treatment hypertension, hand foot syndrome and hypothyroidism were associated with longer PFS (P = 0.0002, 0.0055 and 0.0290, respectively). Ontreatment hypertension, diarrhea, and hand foot syndrome were associated with longer OS (P = 0.0004, 0.0036 and 0.0115, respectively). Conclusions: Baseline and on treatment factors are identified as prognostic markers in mRCC patients treated with axitinib. Our findings might be helpful for clinicians to select the best treatment to individual patients.",
keywords = "Axitinib, Metastasis, Molecular targeted therapy, Outcome, Renal cell carcinoma",
author = "Ryuichi Mizuno and Shuji Mikami and Kimiharu Takamatsu and Toshiaki Shinojima and Eiji Kikuchi and Mototsugu Oya",
year = "2017",
month = "12",
day = "1",
doi = "10.1093/jjco/hyx134",
language = "English",
volume = "47",
pages = "1170--1174",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib

AU - Mizuno, Ryuichi

AU - Mikami, Shuji

AU - Takamatsu, Kimiharu

AU - Shinojima, Toshiaki

AU - Kikuchi, Eiji

AU - Oya, Mototsugu

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background: To elucidate the clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with axitinib. Methods: A total of 58 patients were retrospectively analyzed. All patients received axitinib treatment for mRCC at Keio University hospital in Japan. Baseline clinical factors and on treatment adverse events were assessed to predict survival. Results: The median progression free survival (PFS) for axitinib treatment was 10.9 months (95% CI 5.8-13.5), and the median overall survival (OS) from the start of axitinib treatment was 39.8 months (95% CI 25.9-NR), respectively. The PFS (P < 0.0001) and OS (P = 0.0022) were significantly correlated with the International mRCC Database Consortium (IMDC) classification, respectively. The PFS and OS were significantly longer in patients who received longer prior treatment (P = 0.0424 and 0.0067, respectively). On-treatment hypertension, hand foot syndrome and hypothyroidism were associated with longer PFS (P = 0.0002, 0.0055 and 0.0290, respectively). Ontreatment hypertension, diarrhea, and hand foot syndrome were associated with longer OS (P = 0.0004, 0.0036 and 0.0115, respectively). Conclusions: Baseline and on treatment factors are identified as prognostic markers in mRCC patients treated with axitinib. Our findings might be helpful for clinicians to select the best treatment to individual patients.

AB - Background: To elucidate the clinical prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with axitinib. Methods: A total of 58 patients were retrospectively analyzed. All patients received axitinib treatment for mRCC at Keio University hospital in Japan. Baseline clinical factors and on treatment adverse events were assessed to predict survival. Results: The median progression free survival (PFS) for axitinib treatment was 10.9 months (95% CI 5.8-13.5), and the median overall survival (OS) from the start of axitinib treatment was 39.8 months (95% CI 25.9-NR), respectively. The PFS (P < 0.0001) and OS (P = 0.0022) were significantly correlated with the International mRCC Database Consortium (IMDC) classification, respectively. The PFS and OS were significantly longer in patients who received longer prior treatment (P = 0.0424 and 0.0067, respectively). On-treatment hypertension, hand foot syndrome and hypothyroidism were associated with longer PFS (P = 0.0002, 0.0055 and 0.0290, respectively). Ontreatment hypertension, diarrhea, and hand foot syndrome were associated with longer OS (P = 0.0004, 0.0036 and 0.0115, respectively). Conclusions: Baseline and on treatment factors are identified as prognostic markers in mRCC patients treated with axitinib. Our findings might be helpful for clinicians to select the best treatment to individual patients.

KW - Axitinib

KW - Metastasis

KW - Molecular targeted therapy

KW - Outcome

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85039741063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039741063&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyx134

DO - 10.1093/jjco/hyx134

M3 - Article

C2 - 28977627

AN - SCOPUS:85039741063

VL - 47

SP - 1170

EP - 1174

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 12

ER -